Table 2.
Subgroup analysis of CR.
| Characteristics | CR (n/%) | Non-CR (n/%) | P value |
|---|---|---|---|
| Age | 0.229 | ||
| <18 years | 24 (88.9) | 3 (11.1) | |
| ≥18 years | 12 (100.0) | 0 (0.0) | |
| Gender | 0.709 | ||
| Female | 16 (94.1) | 1 (5.9) | |
| Male | 20 (90.9) | 2 (9.1) | |
| Number of previous chemotherapies | 0.401 | ||
| <4 | 15 (88.2) | 2 (11.8) | |
| ≥4 | 21 (95.5) | 1 (4.5) | |
| Refractory disease | 0.401 | ||
| No | 21 (95.5) | 1 (4.5) | |
| Yes | 15 (88.2) | 2 (11.8) | |
| Relapsed disease | 0.542 | ||
| No | 4 (100.0) | 0 (0.0) | |
| Yes | 32 (91.4) | 3 (8.6) | |
| Bone marrow blasts | 0.323 | ||
| <5% | 27 (90.0) | 3 (10.0) | |
| ≥5% | 9 (100.0) | 0 (0.0) | |
| Extramedullary disease | 0.709 | ||
| No | 16 (94.1) | 1 (5.9) | |
| Yes | 20 (90.9) | 2 (9.1) | |
| CNSL | 0.920 | ||
| No | 25 (92.6) | 2 (7.4) | |
| Yes | 11 (91.7) | 1 (8.3) | |
| BCR/ABL1 | 0.920 | ||
| Negative | 25 (92.6) | 2 (7.4) | |
| Positive | 11 (91.7) | 1 (8.3) | |
| SH2B3 mutation | 0.269 | ||
| Negative | 23 (95.8) | 1 (4.2) | |
| Positive | 13 (86.7) | 2 (13.3) | |
| PAX5 mutation | 0.202 | ||
| Negative | 25 (96.2) | 1 (3.8) | |
| Positive | 11 (84.6) | 2 (15.4) | |
| WBC | 0.079 | ||
| <30 × 109/L | 19 (100.0) | 0 (0.0) | |
| ≥30 × 109/L | 17 (85.0) | 3 (15.0) | |
| Lymphodepletion regimens | 0.920 | ||
| Flu + Cy | 11 (91.7) | 1 (8.3) | |
| Non-Flu + Cy | 25 (92.6) | 2 (7.4) | |
| CAR-T cells | 0.248 | ||
| Anti-CD19 | 24 (96.0) | 1 (4.0) | |
| Anti-CD19 + CD22 | 12 (85.7) | 2 (14.3) |
Data were presented as count. Comparison was determined by χ2 test. P value <0.05 was considered significant.
CR complete remission, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells.